

ORAMED PHARMACEUTICALS INC.  
Form 8-K  
May 09, 2012

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

FORM 8-K

---

CURRENT REPORT

Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 9, 2012

---

ORAMED PHARMACEUTICALS INC.  
(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction  
of incorporation)

000-50298  
(Commission File Number)

98-0376008  
(IRS Employer  
Identification No.)

Hi-Tech Park 2/5 Givat Ram  
PO Box 39098  
Jerusalem, Israel 91390  
(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: 972-2-566-0001

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

ITEM REGULATION FD DISCLOSURE

7.01

On May 8, 2012, Oramed Pharmaceuticals Inc. (the "Company") issued a press release reporting that its wholly owned Israeli subsidiary, Oramed Ltd., was awarded a government grant amounting to a total net of NIS 2 million (approximately \$540,000), from the Office of the Chief Scientist ("OCS") at the Ministry of Industry, Trade and Labor of Israel. This grant was awarded as government participation in research and development expenses for the period between December 2011 to November 2012.

According to the OCS grant terms, Oramed Ltd., is required to pay royalties in the rate of 3% - 5% on sales of products and services derived from technology developed using this and other OCS grants until 100% of the dollar-linked grants amount plus interest are repaid. In the absence of such sales, no payment is required.

A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

ITEM FINANCIAL STATEMENTS AND EXHIBITS.

9.01

(d) Exhibits

99.1 Press Release dated May 8, 2012.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ORAMED PHARMACEUTICALS  
INC.

Dated: May 9, 2012

By: /s/ Nadav Kidron  
Nadav Kidron  
President, CEO and  
Director

---

Exhibit Index

Exhibit Number	Description
-------------------	-------------

99.1	Press Release dated May 8, 2012.
------	----------------------------------

---

---